Go Pro
NASDAQ:PGNY

Progyny (PGNY) Stock Price, News & Analysis

Progyny logo
$26.57 -1.28 (-4.60%)
Closing price 08/11/2026 04:00 PM Eastern
Extended Trading
$26.70 +0.13 (+0.47%)
As of 07:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Progyny Stock (NASDAQ:PGNY)

Advanced

Key Stats

Today's Range
$26.31
$28.23
50-Day Range
$24.99
$32.36
52-Week Range
$16.10
$33.06
Volume
1.30 million shs
Average Volume
1.15 million shs
Market Capitalization
$2.08 billion
P/E Ratio
28.88
Dividend Yield
N/A
Price Target
$34.20
Consensus Rating
Moderate Buy

Company Overview

Progyny, Inc. is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package. Through an in-house network of fertility specialists and clinics, Progyny provides members with access to pre-negotiated pricing, personalized treatment pathways and dedicated care advocates. Complementing these services is a suite of digital resources, including appointment scheduling tools, educational content and real-time treatment tracking, designed to simplify care coordination and reduce administrative burdens.

Founded in 2016, Progyny filed for its initial public offering in October 2019 and began trading on the NASDAQ under the ticker PGNY. The company was established by Michael J. Schulman, who serves as chief executive officer and has guided its growth from a startup to a publicly traded business. Under his leadership, Progyny has expanded its team of clinical advisors and invested in technology to enhance patient engagement and clinical decision support.

Progyny’s services are currently available throughout the United States, with corporate clients spanning technology, finance, manufacturing and other sectors. Headquartered in New York City, the company maintains additional offices in major U.S. markets and collaborates with employers nationwide to provide scalable, outcomes-driven fertility solutions. By combining clinical best practices with data-driven insights, Progyny seeks to set new standards in reproductive healthcare benefits.

AI Generated. May Contain Errors.

Progyny Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

PGNY MarketRank™: 

Progyny scored higher than 95% of companies evaluated by MarketBeat, and ranked 26th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Progyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 8 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    Progyny has a consensus price target of $34.20, representing about 28.7% upside from its current price of $26.57.

  • Amount of Analyst Coverage

    Progyny has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Progyny's stock forecast and price target.
  • Earnings Growth

    Earnings for Progyny are expected to grow by 15.13% in the coming year, from $1.19 to $1.37 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Progyny is 28.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.61.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Progyny is 28.88, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 268.39.

  • Price to Earnings Growth Ratio

    Progyny has a PEG Ratio of 2.02. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Progyny has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Progyny's valuation and earnings.
  • Percentage of Shares Shorted

    6.36% of the float of Progyny has been sold short.
  • Short Interest Ratio / Days to Cover

    Progyny has a short interest ratio ("days to cover") of 4.61.
  • Change versus previous month

    Short interest in Progyny has recently decreased by 3.11%, indicating that investor sentiment is improving.
  • Dividend Yield

    Progyny does not currently pay a dividend.

  • Dividend Growth

    Progyny does not have a long track record of dividend growth.

  • News Sentiment

    Progyny has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 24 news articles for Progyny this week, compared to 5 articles on an average week.
  • Search Interest

    11 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Progyny to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $939,875.00 in company stock.

  • Percentage Held by Insiders

    9.90% of the stock of Progyny is held by insiders.

  • Percentage Held by Institutions

    94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Progyny's insider trading history.
Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PGNY Stock News Headlines

Progyny (PGNY) Stock May Still Trade At A Discount As Earnings Hold Up
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
Progyny, Inc. (PGNY) Q2 2026 Earnings Call Transcript
See More Headlines

PGNY Stock Analysis - Frequently Asked Questions

Progyny's stock was trading at $25.68 at the start of the year. Since then, PGNY stock has increased by 3.5% and is now trading at $26.57.

Progyny, Inc. (NASDAQ:PGNY) released its quarterly earnings data on Thursday, May, 7th. The company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.26 by $0.24. Progyny's revenue for the quarter was down 26.4% on a year-over-year basis.
Read the conference call transcript
.

Progyny's Board of Directors approved a stock buyback program on Tuesday, May 26th 2026, which permits the company to buy back $200,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 10.3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board believes its shares are undervalued.

Progyny (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Top institutional investors of Progyny include BlackRock Inc. (14.81%), Danske Bank A S (0.67%), Bank of New York Mellon Corp (0.53%) and Ieq Capital LLC (0.17%). Insiders that own company stock include Peter Anevski, Michael E Sturmer, David J Schlanger, Allison Swartz, Mark S Livingston, Melissa B Cummings, Geoffrey Clapp, Cheryl Scott and Kevin K Gordon.
View institutional ownership trends
.

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Rambus (RMBS), Voyager Therapeutics (VYGR), Saia (SAIA) and Waste Connections (WCN).

Company Calendar

Last Earnings
5/07/2026
Today
8/12/2026
Next Earnings (Estimated)
10/29/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:PGNY
CIK
1551306
Fax
N/A
Employees
310
Year Founded
2008

Price Target and Rating

High Price Target
$40.00
Low Price Target
$30.00
Potential Upside/Downside
+28.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.92
Trailing P/E Ratio
28.88
Forward P/E Ratio
22.33
P/E Growth
2.02
Net Income
$58.52 million
Net Margins
6.00%
Pretax Margin
9.14%
Return on Equity
15.98%
Return on Assets
10.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.14
Quick Ratio
2.13

Sales & Book Value

Annual Sales
$1.31 billion
Price / Sales
1.59
Cash Flow
$0.70 per share
Price / Cash Flow
37.83
Book Value
$5.91 per share
Price / Book
4.50

Miscellaneous

Outstanding Shares
78,332,000
Free Float
70,577,000
Market Cap
$2.08 billion
Optionable
Optionable
Beta
1.01

Social Links

10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:PGNY) was last updated on 8/12/2026 by MarketBeat.com Staff.
From Our Partners